How the protein TAK1 may drive rhabdomyosarcoma growth
TAK1 signaling in Rhabdomyosarcoma tumorigenesis and growth
['FUNDING_R01'] · UNIVERSITY OF HOUSTON · NIH-11258041
This work tests whether blocking the protein TAK1 can stop rhabdomyosarcoma cells from growing and help them turn into normal muscle, with the goal of helping children and adults with RMS.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF HOUSTON (nih funded) |
| Locations | 1 site (HOUSTON, UNITED STATES) |
| Trial ID | NIH-11258041 on ClinicalTrials.gov |
What this research studies
Researchers will study TAK1 activity in human rhabdomyosarcoma tumor samples and in laboratory-grown RMS cell lines to see how TAK1 affects cancer cell behavior. They will use genetic methods and drug-like inhibitors to block TAK1 and observe effects on tumor cell growth, cancer stem–like traits, and muscle differentiation. Promising findings will be tested in mouse xenograft models to see whether TAK1 inhibition slows tumor formation and promotes myogenic differentiation in living tissues. Overall, the project combines human samples, cell studies, and animal models to explore whether TAK1 is a useful target for future treatments.
Who could benefit from this research
Good fit: People with rhabdomyosarcoma (including alveolar and embryonal subtypes), both children and adults, would be the eventual patient group most likely to benefit from TAK1-targeted approaches.
Not a fit: Patients without rhabdomyosarcoma or whose tumors do not rely on TAK1 signaling are unlikely to benefit directly from this work.
Why it matters
Potential benefit: If successful, the work could identify TAK1 as a new therapeutic target that reduces tumor growth and promotes healthier muscle differentiation in rhabdomyosarcoma patients.
How similar studies have performed: Early preclinical data show TAK1 is active in RMS and that blocking it can reduce tumor-like traits in cells and mice, but clinical testing in patients has not yet been done.
Where this research is happening
HOUSTON, UNITED STATES
- UNIVERSITY OF HOUSTON — HOUSTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: KUMAR, ASHOK — UNIVERSITY OF HOUSTON
- Study coordinator: KUMAR, ASHOK
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.